Scarica l'app Stockscreener
30.65
5.25%
1.53
Dopo l'orario di chiusura:
30.41
-0.24
-0.78%
Vaxcyte Inc Borsa (PCVX) Ultime notizie
Vaxcyte (NASDAQ:PCVX) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
Vaxcyte Stock Plummets 56% in a Month: Here's the Reason - MSN
Vaxcyte Stock Plummets: What’s Next? - timothysykes.com
Vaxcyte, Inc. (PCVX): Billionaire Stanley Druckenmiller’s Top Stock Pick with Huge Upside Potential - Insider Monkey
Vaxcyte stock plunges to 52-week low at $29.53 amid market challenges By Investing.com - Investing.com South Africa
Vaxcyte stock plunges to 52-week low at $29.53 amid market challenges - Investing.com India
Vaxcyte (NASDAQ:PCVX) Price Target Lowered to $137.00 at Bank of America - MarketBeat
InvestingPro Fair Value model correctly predicted Vaxcyte’s decline By Investing.com - Investing.com UK
Vaxcyte (NASDAQ:PCVX) Given New $137.00 Price Target at Bank of America - Defense World
(PCVX) Investment Analysis - news.stocktradersdaily.com
Vaxcyte (PCVX) Stock Falls 45% Despite Positive Vaccine Trial Re - GuruFocus
Vaxcyte ‘narrow’ misses in Phase 2 likely to be ok in Phase 3, says Evercore ISI - Yahoo Finance
BofA lowers Vaxcyte price target, says selloff after infant data ‘overdone’ - TipRanks
Ulta Beauty To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Vaxcyte stock sinks despite Phase II IPD vaccine trial success - Yahoo Finance
Vaxcyte stock up on results from mid-stage trial of its pneumococcal vaccine - MSN
Vaxcyte’s Promising Vaccine Potential and Market Expansion Drive Buy Rating - TipRanks
Goldman Sachs cuts Vaxcyte stock price target to $100 - Investing.com
Goldman Sachs cuts Vaxcyte stock price target to $100 By Investing.com - Investing.com UK
Vaxcyte’s Strong Phase 2 Data and Future Prospects Justify Buy Rating Despite Market Overreaction - TipRanks
Vaxcyte price target lowered to $90 from $140 at Needham - MSN
Vaxcyte sights set on next results after ‘big moment’ with PCV - BioWorld MedTech
Vaxcyte: Shares Tanking On Positive Data? Bad Time To Be A Vaccine Developer (NASDAQ:PCVX) - Seeking Alpha
Sector Update: Health Care Stocks Higher Late Afternoon - MarketScreener
Vaxcyte: Plunge On FDA Top Regulator Resigning Generates Buying Opportunity (NASDAQ:PCVX) - Seeking Alpha
Jefferies maintains Buy on Vaxcyte stock, price target at $146 By Investing.com - Investing.com Canada
Vaxcyte’s VAX-24: Promising Infant Vaccine Results Amidst Investor Concerns - TipRanks
Optimistic Outlook for Vaxcyte: Potential for Improved Vaccine Efficacy in Future Trials - TipRanks
Vaxcyte falls as pneumococcal vaccine data fails to meet lofty investor expectations - TradingView
Jefferies maintains Buy on Vaxcyte stock, price target at $146 - Investing.com India
Daily Digest: Large Asian grocer T&T Supermarket to land in S.F.; Vaxcyte stock plunges - The Business Journals
Biotech Stocks Hammered After A Key FDA Official Resigns - Investor's Business Daily
Vaxcyte stock touches 52-week low at $33.19 amid market shifts - Investing.com
Vaxcyte VAX-24 Vaccine Data Missed Wall Street Expectations, But Fundamentally Still Positive, Mizuho Securities Says - MarketScreener
Guggenheim maintains Vaxcyte stock Buy rating, $160 target By Investing.com - Investing.com Canada
Vaxcyte reports topline results from VAX-24 infant Phase 2 dose-finding study - TipRanks
Vaxcyte plunges despite pneumonia shot results as Marks departure weighs (PCVX:NASDAQ) - Seeking Alpha
Sector Update: Health Care Stocks Fall Pre-Bell Monday - MarketScreener
Vaxcyte’s VAX-24 shows promise in infant vaccine study By Investing.com - Investing.com South Africa
Vaxcyte Announces Positive Phase 2 Results for VAX-24 - TipRanks
Guggenheim maintains Vaxcyte stock Buy rating, $160 target - Investing.com
Vaxcyte Plans To Drop Developing One Pneumococcal Conjugate Vaccine - Benzinga
S&P 500 Futures Fall in Premarket Trading; Vaxcyte, Moderna Lag - Barron's
Vaxcyte's Pneumococcal Conjugate Vaccine Candidate Shows Substantial Immune Response in Infants - Marketscreener.com
Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study - The Manila Times
Vaxcyte stock tumbles following Phase 2 study results By Investing.com - Investing.com Australia
Vaxcyte Announces Positive Topline Results From VAX-24 Infant Phase 2 Dose-Finding Study - MarketScreener
Vaxcyte stock tumbles following Phase 2 study results - Investing.com
Vaxcyte’s VAX-24 shows promise in infant vaccine study - Investing.com
2.51%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):